ArticleMarine drugs2017
Antitumor Effects of Laminaria Extract Fucoxanthin on Lung Cancer.
Article in Marine drugs, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 106 citations in OpenAlex.
- Commercial importance of seaweeds: an overview.Bioresources and bioprocessing · 2025Review
- Co-delivery of fucoxanthin and Twist siRNA using hydroxyethyl starch-cholesterol self-assembled polymer nanoparticles for triple-negative breast cancer synergistic therapy.Journal of advanced research · 2025Article
- Carotenoids Modulate FoxO-Induced Cell Cycle Awrrest in Human Cancer Cell Lines: A Scoping Review.Food science & nutrition · 2025Article
- Fucoxanthin fromMarine drugs · 2025Article
- Review
- Sponge-derived alkaloid AP-7 as a sensitizer to cisplatin in the treatment of multidrug-resistant NSCLC via Chk1-dependent mechanisms.Frontiers in pharmacology · 2024Article
- Article
- Fucoxanthin Inhibits Development of Sigmoid Colorectal Cancer in a PDX Model With Alterations of Growth, Adhesion, and Cell Cycle Signals.Cancer genomics & proteomics · 2023Article
- Anticancer Effects of Fucoxanthin through Cell Cycle Arrest, Apoptosis Induction, and Angiogenesis Inhibition in Triple-Negative Breast Cancer Cells.Molecules (Basel, Switzerland) · 2023Article
- Anticancer Effects of Fucoxanthin through Cell Cycle Arrest, Apoptosis Induction, Angiogenesis Inhibition, and Autophagy Modulation.International journal of molecular sciences · 2022Review
- Natural Products as Anticancer Agents: Current Status and Future Perspectives.Molecules (Basel, Switzerland) · 2022Review
- Fucoxanthin induces apoptosis and reverses epithelial-mesenchymal transition via inhibiting Wnt/β-catenin pathway in lung adenocarcinoma.Discover oncology · 2022Article
- Seaweed and Iodine Intakes and SLC5A5 rs77277498 in Relation to Thyroid Cancer.Endocrinology and metabolism (Seoul, Korea) · 2022Article
- Phytochemical and Potential Properties of Seaweeds and Their Recent Applications: A Review.Marine drugs · 2022Review
- An Overview of Potential Seaweed-Derived Bioactive Compounds for Pharmaceutical Applications.Marine drugs · 2022Review
- Fucoxanthin: A Promising Phytochemical on Diverse Pharmacological Targets.Frontiers in pharmacology · 2022Review
- Anti-Inflammatory and Anticancer Effects of Microalgal Carotenoids.Marine drugs · 2021Review
- Article
- Advances in Studies on the Pharmacological Activities of Fucoxanthin.Marine drugs · 2020Review
- Fucoxanthin attenuates LPS-induced acute lung injury via inhibition of the TLR4/MyD88 signaling axis.Aging · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is the leading cause of cancer mortality worldwide and non-small-cell lung cancer (NSCLC) is the most common type. Marine plants provide rich resources for anticancer drug discovery. Fucoxanthin (FX), a
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.